PharmAbcine Inc - Product Pipeline Review

Global Markets Direct’s, ‘PharmAbcine Inc - Product Pipeline Review - 2016’, provides an overview of the PharmAbcine Inc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by PharmAbcine Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of PharmAbcine Inc

The report provides overview of PharmAbcine Inc including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses PharmAbcine Inc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features PharmAbcine Inc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate PharmAbcine Inc’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for PharmAbcine Inc

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding PharmAbcine Inc’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

PharmAbcine Inc ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

PharmAbcine Inc Snapshot 6

PharmAbcine Inc Overview 6

Key Facts 6

PharmAbcine Inc - Research and Development Overview 7

Key Therapeutic Areas 7

PharmAbcine Inc - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

PharmAbcine Inc - Pipeline Products Glance 12

PharmAbcine Inc - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

PharmAbcine Inc - Drug Profiles 14

Monoclonal Antibody to Antagonize c-Met for Oncology and Inflammatory Disorders - Drug Profile 14

Product Description 14

Mechanism Of Action 14

R&D Progress 14

Monoclonal Antibody to Antagonize EGFR for Oncology and Inflammatory Disorders - Drug Profile 15

Product Description 15

Mechanism Of Action 15

R&D Progress 15

Monoclonal Antibody to Antagonize HER2 for Oncology and Inflammatory Disorders - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

Monoclonal Antibody to Antagonize IGFR-1 for Oncology and Inflammatory Disorders - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

Monoclonal Antibody to Antagonize VEGFR-1 for Oncology and Inflammatory Disorders - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

Monoclonal Antibody to Antagonize VEGFR-3 for Oncology and Inflammatory Disorders - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

Monoclonal Antibody to Inhibit DLL4 for Oncology and Inflammatory Disorders - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

Monoclonal Antibody to Inhibit EPCAM for Oncology and Inflammatory Disorders - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

Monoclonal Antibody to Target CD-20 for Oncology and Inflammatory Disorders - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

PMC-001 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

PMC-002 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

PMC-201 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

TTAC-0001 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

PharmAbcine Inc - Pipeline Analysis 29

PharmAbcine Inc - Pipeline Products by Target 29

PharmAbcine Inc - Pipeline Products by Route of Administration 31

PharmAbcine Inc - Pipeline Products by Molecule Type 32

PharmAbcine Inc - Pipeline Products by Mechanism of Action 33

PharmAbcine Inc - Dormant Projects 35

PharmAbcine Inc - Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

PharmAbcine Inc, Key Facts 6

PharmAbcine Inc - Pipeline by Indication, 2016 8

PharmAbcine Inc - Pipeline by Stage of Development, 2016 ...

List of Tables

PharmAbcine Inc, Key Facts 6

PharmAbcine Inc - Pipeline by Indication, 2016 8

PharmAbcine Inc - Pipeline by Stage of Development, 2016 10

PharmAbcine Inc - Monotherapy Products in Pipeline, 2016 11

PharmAbcine Inc - Preclinical, 2016 12

PharmAbcine Inc - Discovery, 2016 13

PharmAbcine Inc - Pipeline by Target, 2016 30

PharmAbcine Inc - Pipeline by Route of Administration, 2016 31

PharmAbcine Inc - Pipeline by Molecule Type, 2016 32

PharmAbcine Inc - Pipeline Products by Mechanism of Action, 2016 34

PharmAbcine Inc - Dormant Developmental Projects,2016 35

PharmAbcine Inc, Other Locations 36

List of Figures

List of Figures

PharmAbcine Inc - Pipeline by Top 10 Indication, 2016 8

PharmAbcine Inc - Pipeline by Stage of Development, 2016 10

PharmAbcine Inc ...

List of Figures

PharmAbcine Inc - Pipeline by Top 10 Indication, 2016 8

PharmAbcine Inc - Pipeline by Stage of Development, 2016 10

PharmAbcine Inc - Monotherapy Products in Pipeline, 2016 11

PharmAbcine Inc - Pipeline by Top 10 Target, 2016 29

PharmAbcine Inc - Pipeline by Molecule Type, 2016 32

PharmAbcine Inc - Pipeline Products by Top 10 Mechanism of Action, 2016 33

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports